In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.
Harrow today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for several products it acquired from Santen Pharmaceutical Co. Ltd.
In July 2023, Harrow received certain United States (US) and Canadian commercial rights for six branded products from Santen. Harrow completed the transfer of the NDAS for the following products:
In July, Harrow announced the acquisition of the US commercial rights of these products. To date, Harrow has been receiving profit transfers on these products. However, with the transfer of the NDAs completed, Harrow has launched these products in the U.S. under the Harrow name.
Mark L. Baum, CEO of Harrow, noted the company is focused on forming commercial strategies.
“With the completion of the NDA transfer process for the branded ophthalmic portfolio that we recently acquired, our marketing and sales teams are hard at work implementing commercial strategies aimed at increasing brand awareness and sales for these products,” Baum said. “These products and others we acquired this year support a growing awareness among US eyecare professionals that Harrow is exclusively focused on and committed to serving US eyecare professionals with a full range of high-quality, accessible, and affordable products they need to care for their patients.”
Product orders for Flarex, Natacyn, Torbradex ST, Verkazia and Zerviate can be made directly through Harrow’s dedicated customer service ordering partner, Cardinal’s Cordlogistics, which includes a wholesaler distribution system encompassing McKesson and AmerisourceBergen.